CHALLENGES IN CANCER THERAPY
PANCREATIC CANCER PROGNOSES
survival rate within 5 years
Pancreatic cancer is one of the most lethal diseases with a 5-year survival rate of 8%. The 10-year survival rate sits at 1%.
of patients are diagnosed too late
85% of pancreatic cancer patients are diagnosed at the point when tumors are not surgically resectable. This leaves chemotherapy and radiotherapy as their only treatment options with generally poor health outcomes.
drug molecules retained in tumors
Solid tumors have considerable barriers that result in less than 0.01% delivered drug molecules retainment.
We have ambitions to develop a novel targeted drug delivery platform via nanoparticles to overcome drug delivery barriers in various human cancers and other non-oncological diseases.
SHORT GOAL #1
Our first step is developing targeted stroma-breaking hyaluronic acid nanoparticle drug (MIGRA-NP01) primarily focused on drug resistant pancreatic cancer.
SHORT GOAL #2
An additional goal is developing targeted stroma-breaking co-delivery approaches for enhancement of therapeutic efficacy of chemotherapeutic drugs, small molecular drugs, and immunotherapeutic agents.